Frexalimab clinical trials
Also written SAR441344.
How each study uses frexalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the frexalimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2023 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Cholestyramine Resin (1) · Charcoal (1) · Brivekimig (1) · Rilzabrutinib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 2 in phase 3
Studies that test frexalimab, phase 3 first.
- May 2027Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisPhase 3 · Sanofi
- Jul 2027Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisPhase 3 · Sanofi
- Dec 2026A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseasePhase 2 · Sanofi
- Apr 2027Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)Phase 2 · Sanofi
Studies
Open first, then newest update. How each study uses frexalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple SclerosisNot yet recruitingPhase 3SanofiNCT07930624Written as Frexalimab
- A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseRecruitingPhase 2SanofiNCT06500702Written as frexalimab
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney TransplantationRecruitingPhase 2/3SanofiNCT07412470Written as Frexalimab
- Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisRecruitingPhase 3SanofiNCT07325292Written as Frexalimab
- Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisActive, not recruitingPhase 3SanofiNCT06141486Written as Frexalimab
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)Active, not recruitingPhase 2SanofiNCT06111586Written as Frexalimab
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisActive, not recruitingPhase 2SanofiNCT04879628Written as SAR441344 IV
- Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusActive, not recruitingPhase 2SanofiNCT05039840Written as SAR441344 IV
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisActive, not recruitingPhase 3SanofiNCT06141473Written as Frexalimab
- Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)CompletedPhase 2SanofiNCT04572841Written as SAR441344
- Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult SubjectsCompletedPhase 1SanofiNCT05845996Written as SAR441344
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call frexalimab · ClinicalTrials.gg INT018372
- UNII (FDA) WO7SFK0ENJFREXALIMABOne source FDA
- NCI Thesaurus C190493FrexalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WO7SFK0ENJ | FREXALIMAB | One source FDA |
| NCI Thesaurus | C190493 | Frexalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.